[
  {
    "ts": null,
    "headline": "Bionic Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts to 2033",
    "summary": "The global Bionic Devices Market is projected to surge to approximately USD 11.90 billion by 2033, from USD 6.22 billion in 2025, at a CAGR of 8.45%. Key growth drivers include technological advancements in wearable robotics, rising demand for non-invasive treatments, and increasing chronic illnesses. AI innovations and healthcare spending further enhance bionic devices' performance. Leading companies in this field, such as Abbott Laboratories, Abiomed, and Edwards Lifesciences, are driving glob",
    "url": "https://finnhub.io/api/news?id=87a6aea6b912cb1c8c85d05cc5c7484001020e9e922f62b35ca79f2cf02a1dc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771431180,
      "headline": "Bionic Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts to 2033",
      "id": 139137897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The global Bionic Devices Market is projected to surge to approximately USD 11.90 billion by 2033, from USD 6.22 billion in 2025, at a CAGR of 8.45%. Key growth drivers include technological advancements in wearable robotics, rising demand for non-invasive treatments, and increasing chronic illnesses. AI innovations and healthcare spending further enhance bionic devices' performance. Leading companies in this field, such as Abbott Laboratories, Abiomed, and Edwards Lifesciences, are driving glob",
      "url": "https://finnhub.io/api/news?id=87a6aea6b912cb1c8c85d05cc5c7484001020e9e922f62b35ca79f2cf02a1dc5"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=78001be0761fe2c048f7041fbdd6d40e59c3f3f8f236bd36f71a3ee5bd5d8cd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771423203,
      "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 139137898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=78001be0761fe2c048f7041fbdd6d40e59c3f3f8f236bd36f71a3ee5bd5d8cd9"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For February",
    "summary": "IXJ: Healthcare Sector Dashboard For February",
    "url": "https://finnhub.io/api/news?id=4c7217c375ec3588b7d733d67e76ed36acfbee5d367368b6809a501d5b536ff7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771408800,
      "headline": "IXJ: Healthcare Sector Dashboard For February",
      "id": 139136343,
      "image": "",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4c7217c375ec3588b7d733d67e76ed36acfbee5d367368b6809a501d5b536ff7"
    }
  },
  {
    "ts": null,
    "headline": "How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS)",
    "summary": "Exact Sciences’ story has shifted toward the US$105 per share Abbott offer becoming the key anchor for what many investors watch as a reference value, and that is now reflected in a fair value estimate that holds steady at US$105.81 per share. Behind that headline number, the discount rate has nudged slightly lower from 7.25% to 7.24% and revenue growth assumptions have moved from 12.30% to 11.03%, as analysts increasingly frame their models around the agreed deal price rather than longer...",
    "url": "https://finnhub.io/api/news?id=113e8387baee24831e02553e6059b500fe3eede4c4040d25b063e3fabd6efa81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771376897,
      "headline": "How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS)",
      "id": 139128234,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Exact Sciences’ story has shifted toward the US$105 per share Abbott offer becoming the key anchor for what many investors watch as a reference value, and that is now reflected in a fair value estimate that holds steady at US$105.81 per share. Behind that headline number, the discount rate has nudged slightly lower from 7.25% to 7.24% and revenue growth assumptions have moved from 12.30% to 11.03%, as analysts increasingly frame their models around the agreed deal price rather than longer...",
      "url": "https://finnhub.io/api/news?id=113e8387baee24831e02553e6059b500fe3eede4c4040d25b063e3fabd6efa81"
    }
  }
]